EADV 2024: scientific presentations supported by Galderma

Galderma, the pure-play dermatology category leader, will be showcasing its innovative, science-based portfolio that spans the full spectrum of the fast-growing dermatology market at the 33rd European Academy of Dermatology and Venereology (EADV) congress taking place in Amsterdam, September 25-28, 2024. Details on scientific presentations supported by Galderma at EADV 2024 can be found below. Therapy area First author Abstract title and number Presentation time and location Nemolizumab* Prurigo nodularis FJ. Legat Abstract #7987 Durability of response to nemolizumab in patients with moderate-to-severe prurigo nodularis: Results from a randomised placebo-controlled withdrawal Phase 3b study Late-breaking presentation Wednesday 25 September 2:15 – 2:30 pm CET Auditorium Atopic dermatitis D. Thaçi Abstract #7885 Nemolizumab long-term safety and efficacy up to 56 weeks in ARCADIA open-label extension study in adolescents and adults with moderate-to-severe atopic dermatitis Late-breaking presentation Wednesday 25 September 3 – 3:15 pm CET Auditorium Atopic dermatitis E. Guttman-Yassky Abstract #8052 Tape-strips transcriptomic analysis from patients with moderate to severe atopic dermatitis treated with nemolizumab Late-breaking presentation Wednesday 25 September 4:30 – 4:45 pm CET Auditorium Prurigo nodularis M. Metz (presenting: FJ. Legat) Abstract #6224 Laboratory safety of nemolizumab in prurigo nodularis: Results from two phase 3 trials and one open-label extension study E-poser & oral presentation Thursday September 26 4:30 – 4:40 pm CET Open Stage Atopic dermatitis R. Sidbury Abstract #P0694 Efficacy and Safety of Nemolizumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Sub analysis from Two Phase 3 Randomized Clinical Trials (ARCADIA 1 and ARCADIA 2) after 16 weeks E-Posters E-Posters will be available for viewing in the e-Poster area, in the Wignacourt, level 6 of the Hilton Hotel - Conference Centre Atopic dermatitis / Prurigo nodularis N. Wagner Abstract #P1025 Absence of clinically impactful immunogenicity of nemolizumab in long-term treatment of patients with atopic dermatitis and prurigo nodularis Prurigo nodularis N. Wagner Abstract #P1026 Exposure response to support dose selection of nemolizumab in patients with prurigo nodularis Prurigo nodularis S. Ständer Abstract #P1040 Nemolizumab elicits an early and rapid itch response in prurigo nodularis within 2 days: A post hoc analysis of OLYMPIA 1 & 2 data Atopic dermatitis P. Lio Abstract #P0522 Incidence of comorbidities in a cohort of patients during the first year following initiation of systemic treatment for atopic dermatitis: a retrospective matched-control analysis of a US claims database Acne & sensitive skin Acne J. Tan Abstract #P0028 Phase 4 Analyses: Trifarotene Reduces Atrophic Acne Scars Across All Skin Types With Greater Effect in Subjects with Higher Baseline Acne and Acne Scarring Severity Short oral presentation Thursday September 26 3:15 – 3:25pm CET Open Stage Acne A. Alexis Abstract #P0196 Unlocking the patient perspective: Exploring acne-induced post-inflammatory hyperpigmentation in the Phase 4 LEAP study E-Posters E-Posters will be available for viewing in the e-Poster area, in the Wignacourt, level 6 of the Hilton Hotel - Conference Centre Acne J. Tan Abstract #P0028 Phase 4 Analyses: Trifarotene Reduces Atrophic Acne Scars Across All Skin Types With Greater Effect in Subjects with Higher Baseline Acne and Acne Scarring Severity Acne JQ. Del Rosso Abstract #P0152 Efficacy, Tolerability, And Acceptability of A 2.6% Benzoyl Peroxide Acne Cleanser Specifically Designed for Sensitive Skin Acne M. Clément Abstract #P0140 Dermal patch: acne-prone skin management in modern dermatology Acne I. Berlin Abstract #P0139 Global perspective of acne and sensitive skin association in a multiethnic survey Acne B. Stephan Abstract #P0153 Epidemiology and health care of juvenile and late-onset acne – claims data analysis Skin sensitivity M. Morse Abstract #P1165 Efficacy and safety of topical formulations on sensitive skin across 4 main ethnicities: A meta-analysis of clinical trials Sensitive skin E. McCormick Abstract #P2658 Sensitive Skin: A Survey of Dermatology Resident Physicians’ Perspectives and Educational Exposures Sensitive skin C. Whiting Abstract #P2657 Primary Hyperhidrosis and Sensitive Skin Syndrome: A National Pilot Survey Sensitive skin C. Ye Abstract #P1848 A comparison between Lactic Acid Sting test and Sensitive Scale-10 in the diagnosis of Sensitive Skin Dermatological Skincare Atopic dermatitis TQ. Nguyen Abstract #P0647 Comparison of Two OTC Itch Relief Products After Single Application E-Posters E-Posters will be available for viewing in the e-Poster area, in the Wignacourt, level 6 of the Hilton Hotel - Conference Centre Atopic dermatitis P. Lio Abstract #P0659 The Effect of a Soothing Moisturizer on Ceramide Levels in Patients with Eczema-Prone Skin Atopic dermatitis TQ. Nguyen Abstract #P0646 Comparison of a Soothing Moisturizer Versus Itch Relief Moisturizing Lotion on Hydration and TEWL in Patients with Eczema-Prone Skin Atopic dermatitis S. Anjuwon Abstract #P0633 A novel 2-step regimen improves severity, itch, and quality of life in an atopic dermatitis prone skin in a multi-ethnic population: a randomized clinical study Atopic dermatitis K. Hawley Abstract #P0660 A Novel 3-Step OTC Regimen Improves Eczema-Prone Skin Severity, Itch, and Life Quality: Randomized Study Psoriasis FG. Hougeir Abstract #P3317 Efficacy and Tolerability of a Sensitive Skin Cleansing and Moisturizing Regimen in Patients with Plaque Psoriasis Undergoing Prescription Treatment Skin hydration TQ. Nguyen Abstract #P1169 Heatmap Evaluation of Facial Hydration Skin hydration M. Afriat Abstract #P1166 A skincare regimen specifically designed for sensitive skin improves skin quality and hydration Wound healing AS. Farberg Abstract #P3676 Safety and Efficacy of a Healing Ointment as a Post-Surgical Wound Care Babies/Diaper rash TQ. Nguyen Abstract #P2872 Subject Perception of an OTC Healing Ointment to Prevent/Heal Diaper Rash in Infants Injectable aesthetics C. Blanché Abstract #P1167 Improved outcomes in injectable aesthetic procedures when combined with a customized skincare regimen All authors are paid consultants or employees of Galderma. *Nemolizumab is an investigational drug in atopic dermatitis. Galderma received approval for its use in adults with prurigo nodularis in the U.S. (under the brand name Nemluvio®) in August 2024.

The release as fetched from its publisher. galderma.com ↗